Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Completed · Phase 2

Conditions studied: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy

In brief

The purpose of the study is to study the clinical effects of the investigational drug, SB-509 versus placebo in patients with diabetic neuropathy.

Key facts

Study ID

NCT00406458

Run by

Sangamo Therapeutics

People needed

110

Starts

2006-11-01

Expected to finish

2009-05-01

Last updated by the study team

2012-11-01

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Coordinated Clinical Research — La Jolla, California, United States
• Advanced Medical Research, LLC — Lakewood, California, United States
• SF Clinical Research Center — San Francisco, California, United States
• Diablo Clinical Research — Walnut Creek, California, United States
• Bradenton Research Center — Bradenton, Florida, United States
• University of Miami, Diabetes Research Institute — Miami, Florida, United States
• Neurology Clinical Research — Sunrise, Florida, United States
• University of Kansas Medical Center — Kansas City, Kansas, United States
• Creighton Diabetes Center — Omaha, Nebraska, United States
• Upstate Clinical Research — Albany, New York, United States
• Peripheral Neuropathy Center, Weill Medical College of Cornell University — New York, New York, United States
• Altoona Center for Clinical Research — Duncansville, Pennsylvania, United States
• Nerve and Muscle Center of Texas — Houston, Texas, United States
• DGD Research — San Antonio, Texas, United States
• Instituto Mexicano de Investigación Clinica — Mexico City, Col. Roma, Mexico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.